As tumor-infiltrating CD4+ or FoxP3+ T cells are associated with poor prognosis in human BCa, this suggested that RANKL inhibition could be used in combination with other therapies to improve outcomes, including with ICIs, which are associated with substantially disparate responses in different tumor types and patients [128]. Here, FOXP3 is linked to neoplasm.